For the quarter ending 2026-03-31, ISCO had -$60K decrease in cash & cash equivalents over the period. $98K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Product sales | 2,315 | 9,100 | - | - |
| Cost of sales | 954 | 4,033 | - | - |
| General and administrative | 1,122 | 3,532 | - | - |
| Selling and marketing | 273 | 1,118 | - | - |
| Research and development | 156 | 684 | - | - |
| Total operating expenses | 2,505 | 9,367 | - | - |
| Loss from operations | -190 | -267 | - | - |
| Total other expense, net | -30 | -151 | - | - |
| Net loss | -220 | -348 | 57 | -127 |
| Stock-based compensation | 64 | 64 | 63 | 161 |
| Depreciation and amortization | 34 | 54 | 56 | 109 |
| Non-cash operating lease expense | 83 | 81 | 79 | 150 |
| Interest expense on related party note payable | 33 | 35 | 35 | 75 |
| Change in inventory reserve | 8 | 16 | -26 | 55 |
| Accounts receivable | 68 | -292 | -86 | 43 |
| Inventories | 264 | -71 | -12 | 470 |
| Prepaid expenses and other current assets | 135 | 19 | -107 | 146 |
| Accounts payable | 269 | -97 | -132 | 211 |
| Accrued liabilities | 413 | -24 | -199 | 124 |
| Operating lease liabilities | -96 | -93 | -89 | -172 |
| Net cash provided by operating activities | 121 | 32 | 49 | -73 |
| Purchases of property and equipment | 23 | 3 | 3 | 37 |
| Payments for patent licenses | 8 | 2 | - | - |
| Net cash used in investing activities | -31 | -5 | -3 | -37 |
| Payments on related party note payable | 150 | 0 | 0 | 200 |
| Net cash used in financing activities | -150 | 0 | 0 | -200 |
| Net (decrease) increase in cash | -60 | 27 | 46 | -310 |
| Cash, beginning of period | 993 | 966 | 1,230 | - |
| Cash, end of period | 933 | 993 | 966 | - |
International Stem Cell CORP (ISCO)
International Stem Cell CORP (ISCO)